Propofol Injection for Daily Headache
Chronic Headache, Analgesic Rebound Headache, Chronic Daily Headache
About this trial
This is an interventional treatment trial for Chronic Headache focused on measuring Chronic Headache, Analgesic Rebound Headache, Chronic Daily Headache, Headache, Intractable, Randomised controlled trial, Propofol
Eligibility Criteria
Inclusion criteria Adult subjects (18-65 years) with CDH by the criteria of Silberstein and Lipton.41 i.e. on the basis of pre-randomization history suffer chronic headaches lasting more than 4 hours a day for more than 15 days a month. Previously investigated to exclude serious treatable pathology. On the basis of the pre-randomization headache diary: the average pain intensity during each episode should be at least 5 /10 on the Numerical Rating Scale (NRS) on 4 days out of 7. Quality of life and function should be impaired as evidenced by a (pre-randomization) Headache Disability Index (HDI) of at least 40. Exclusion criteria History of the following: Known or suspected allergy to propofol, intralipid or midazolam, In emergency or life-threatening situations, Those having language barriers (e.g. illiterate, not English-speaking, dysphasic), Known or suspected difficult airway or sleep apnea, Severe respiratory disease, Neuromuscular disease, Seizure disorder, Severe cardiac disease, Severe gastroesophageal reflux disease, Pancreatitis, Lipid disorders, Receiving Total Parenteral Nutrition, Body mass index > 35, diabetes or major endocrine disorder, Hepatic or renal failure, Unstable psychiatric disorder, Known drug abuse, Pregnancy, Cognitively impaired.
Sites / Locations
- Multidisciplinary Pain Centre, Univ. Alta Hospital